Publications by authors named "Maria-Jesus Rubio"

Claim this Profile
M
Management and Clinical Outcomes of Patients with Advanced Ovarian Cancer in Routine Clinical Practice in Spain: The OVOC Study.
Maria Quindós-Varela, Diego Soto de Prado-Otero, Alejandro Gallego, Yolanda García, Eva Guerra, María Jesús Rubio

Oncol Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients.
François Cherifi, Isabelle Ray-Coquard, Maria Jesus Rubio, Xavier Paoletti, Domenica Lorusso

Future Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.
Ana Oaknin, Bradley J Monk, Andreia Cristina de Melo, Hee Seung Kim, Yong Man Kim, Maria Jesús Rubio

Eur J Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.
Mansoor R Mirza, Line Bjørge, Frederik Marmé, René DePont Christensen, Marta Gil-Martin, Maria Jesús Rubio

Gynecol Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.
Antonio González-Martín, María Jesús Rubio, Florian Heitz, René Depont Christensen, Nicoletta Colombo

J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study.
María Jesús Rubio, Aránzazu Manzano, Luis Miguel de Sande, Purificación Estévez-García, María Del Mar Gordon

BMC Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study).
Beatriz Tavira, Teresa Iscar, Luis Manso, Ana Santaballa, Marta Gil-Martin, María Jesús Rubio

Clin Cancer Res· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García, Guillermo Villacampa, Munetaka Takekuma, Maria Jesús Rubio

Lancet· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus.
Andrés Redondo, Pilar Barretina, Alejandro Pérez-Fidalgo, María Jesús Rubio, Antonio González-Martín

J Gynecol Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03.
Jesus Garcia-Donas, Alicia Hurtado, Laia Garrigos, Ana Santaballa, Andres Redondo, Maria Jesus Rubio

Clin Transl Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
Thomas J Herzog, Sandro Pignata, Sharad A Ghamande, Maria-Jesús Rubio, Keiichi Fujiwara

Gynecol Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Real-World Gynaecological Cancer Clinical Registry with Associated Biospecimens: A Collaborative Model to Promote Translational Research between GEICO and the Spanish Biobank Network.
José Antonio López-Guerrero, Marta Mendiola, José Alejandro Pérez-Fidalgo, Ignacio Romero, Ana Torres, María Jesús Rubio

Cancers (Basel)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study.
Andres Poveda, Raquel Lopez-Reig, Ana Oaknin, Andres Redondo, Maria Jesus Rubio

Cancers (Basel)· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Elias et al.: Multiproxy evidence of widespread landscape disturbance in multiple Azorean lakes before the Portuguese arrival.
Pedro M Raposeiro, Armand Hernández, Sergi Pla-Rabes, Vítor Gonçalves, Roberto Bao, María Jesús Rubio

Proc Natl Acad Sci U S A· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Climate change facilitated the early colonization of the Azores Archipelago during medieval times.
Pedro M Raposeiro, Armand Hernández, Sergi Pla-Rabes, Vítor Gonçalves, Roberto Bao, María Jesús Rubio

Proc Natl Acad Sci U S A· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of advanced ovarian cancer in Spain: an expert Delphi consensus.
Andres Redondo, Ana Oaknin, Maria Jesus Rubio, Maria-Pilar Barretina-Ginesta, Ana de Juan

J Ovarian Res· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
Vivek Subbiah, Luis Paz-Ares, Benjamin Besse, Victor Moreno, Solange Peters, María Jesús Rubio

Lung Cancer· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO).
María Jesús Rubio, María José Lecumberri, Silvia Varela, Jesús Alarcón, María Eugenia Ortega

Gynecol Oncol Rep· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
José Trigo, Vivek Subbiah, Benjamin Besse, Victor Moreno, Rafael López, María Jesús Rubio

Lancet Oncol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis